1451272-46-0

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 24242-19-1 5-aminonicotinic acid 
• 36052-25-2 5-amino-nicotinic acid methyl ester 
• 23095-05-8 5-bromo-2-methoxybenzenesulfonyl chloride 

Downstream Products

• 1451274-34-2 5-(5-bromo-2-methoxyphenylsulfonamido)nicotinic acid 
• 1451272-49-3 cyclohexyl 5-(5-bromo-2-methoxyphenylsulfonamido)nicotinate 
• 1451272-62-0 5-(5-bromo-2-methoxybenzenesulfonylamino)nicotinamide 
• 1451272-65-3 5-(5-bromo-2-methoxyphenylsulfonamido)-N-cyclohexylnicotinamide 
• 1451272-61-9 5-(5-bromo-2-methoxybenzenesulfonylamino)-N-methylnicotinamide 

Relevant academic research and scientific papers

Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor

Tissue-nonspecific alkaline phosphatase (TNAP) is an ectoenzyme crucial for bone matrix mineralization via its ability to hydrolyze extracellular inorganic pyrophosphate (ePPi), a potent mineralization inhibitor, to phosphate (Pi). B

SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS

Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper- mineralization.